Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider, today announced that it has filed timely a formal ...

Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

SHENZHEN, China, Oct. 8, 2024 /PRNewswire/ -- BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider ...

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...

BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply ...

纽约 - 纳斯达克证券交易所宣布,经过长达一个月的停牌后,BAIYU Holdings, Inc. (NASDAQ: BYU)的股票将于周三恢复交易。该公司股票于2024年9月5日东部时间晚上7:50暂停交易,交易所现定于2024年10月9日东部时间上午9:00解除停牌。

BAIYU Holdings shares touched a 52-week low as the stock returned to Nasdaq, over a month after the Securities and Exchange Commission temporarily suspended trading. However, shares could possibly ...